In a significant development for its pharmaceutical division, Johnson & Johnson has received U.S. regulatory clearance for a novel psoriasis treatment. The Food and Drug Administration (FDA) granted approval on March 18 for ICOTYDE™ (icotrokinra), marking it as the first-ever oral peptide IL-23 receptor antagonist for managing moderate-to-severe plaque psoriasis.
Market Impact and Financial Prospects
The commercial outlook for this new therapy is substantial. Industry analysts project that ICOTYDE could eventually generate peak annual sales exceeding $5 billion. This estimate is driven by the sizable patient population expected to favor a convenient oral administration over existing injectable treatments. The approval is likely to bolster confidence in the growth trajectory of Johnson & Johnson’s innovative medicine segment, a sentiment echoed by HSBC, which raised its assessment of the company earlier this week.
Reflecting this positive momentum, the corporation’s shares currently trade approximately 23% above their 200-day moving average. Since the start of the year, the stock has advanced close to 17%.
A New Therapeutic Option Emerges
The introduction of ICOTYDE represents a notable shift in the treatment paradigm. Until now, patients with this condition have largely relied on injectable biologic drugs. This new medication provides the first oral alternative with comparable efficacy, a potential game-changer for patient acceptance and adherence.
Should investors sell immediately? Or is it worth buying Johnson & Johnson?
The drug’s development was conducted in collaboration with Protagonist Therapeutics. Its approval was based on the robust ICONIC clinical program, which involved four Phase 3 trials encompassing roughly 2,500 participants.
Clinical Data Underpinning the Approval
Trial results demonstrated strong effectiveness and a favorable safety profile. By week 16, about 70% of patients achieved clear or almost clear skin, measured as an Investigator’s Global Assessment (IGA) score of 0 or 1. Furthermore, 55% attained a PASI-90 response, indicating a 90% improvement in the Psoriasis Area and Severity Index.
Safety data monitored through week 52 revealed no new warning signals. The incidence of adverse events was only 1.1 percentage points higher than that observed in the placebo group.
Ad
Johnson & Johnson Stock: Buy or Sell?! New Johnson & Johnson Analysis from March 19 delivers the answer:
The latest Johnson & Johnson figures speak for themselves: Urgent action needed for Johnson & Johnson investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 19.
Johnson & Johnson: Buy or sell? Read more here...
